Skip to main content
Jiangsu Hualan New Pharmaceutical Material Co., Ltd. logo

Jiangsu Hualan New Pharmaceutical Material Co., Ltd. — Investor Relations & Filings

Ticker · 301093 ISIN · CNE100004YH2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 778 across all filing types
Latest filing 2026-05-25 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 301093

About Jiangsu Hualan New Pharmaceutical Material Co., Ltd.

https://www.hua-lan.com

Jiangsu Hualan New Pharmaceutical Material Co., Ltd. specializes in the research, development, production, and distribution of high-quality pharmaceutical packaging materials. The company's primary product portfolio includes various types of butyl rubber stoppers, aluminum-plastic combination caps, and polyisoprene liners designed for injectable drugs, infusion sets, and blood collection systems. These products are engineered to ensure the safety, stability, and integrity of pharmaceutical formulations, meeting rigorous international quality standards and GMP requirements. Hualan serves a global clientele, providing critical sealing solutions for vaccines, antibiotics, and biological products. The company emphasizes technological innovation and advanced manufacturing processes to maintain its position as a leading supplier in the pharmaceutical primary packaging sector.

Recent filings

Filing Released Lang Actions
关于全资子公司投资设立全资孙公司的进展公告
Capital/Financing Update Classification · 75% confidence The document is an announcement by Jiangsu Hualan Pharmaceutical New Materials Co., Ltd. regarding the progress of its wholly-owned subsidiary’s capital investment to establish a new sub-subsidiary, including details of capital injection (registered capital and capital reserve). This is not an annual or interim report, nor a merger/acquisition or fundraising through external financing; rather it reports changes in capital structure via internal investment. Therefore it best fits the Capital/Financing Update category (CAP).
2026-05-25 Chinese
北京植德律师事务所关于江苏华兰药用新材料股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 90% confidence The document is a law firm’s legal opinion (“法律意见书”) on the legitimacy of convening, qualifications of participants, and voting procedures/results of the company’s 2025 annual shareholders’ meeting. It is not the company’s own financial report, proxy statement, or earnings release, but rather a compliance/legal opinion and certification accompanying the meeting. This best fits the “Regulatory Filings (RNS)” category as a compliance document/officer certification under the fallback “Regulatory Filings” classification.
2026-05-18 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is an announcement of the resolutions and voting results from the company’s 2025 Annual General Shareholders’ Meeting, detailing attendance, vote counts for each proposal, and legal opinions. It does not present financial statements itself but reports on the meeting decisions and voting outcomes. This fits the "Declaration of Voting Results & Voting Rights Announcements" category.
2026-05-18 Chinese
关于举办2025年度网上业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling of the 2025 annual performance explanation meeting (业绩说明会), which is a type of earnings or performance presentation event. It mentions the date and time of the online meeting and invites investors to participate and submit questions. The document references the 2025 annual report but does not contain the report itself or detailed financial data. The document length is short (791 characters), and it serves as a notice for an upcoming event rather than the event transcript or report. Therefore, it fits best under Investor Presentation (IP) as it is a detailed presentation event for investors focusing on financials and strategy.
2026-05-08 Chinese
2026年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "江苏华兰药用新材料股份有限公司2026年第一季度报告" which translates to "Jiangsu Hualan Pharmaceutical New Materials Co., Ltd. 2026 First Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and explanations of financial performance for the first quarter of 2026. The document includes comprehensive financial metrics, shareholder information, and management commentary on financial results. The presence of quarterly financial statements and detailed financial analysis confirms this is a quarterly financial report. It is not an announcement or a brief summary but a full report with substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-04-23 Chinese
2025年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled '审计报告' (Audit Report) for 江苏华兰药用新材料股份有限公司 covering the fiscal year from January 1, 2025 to December 31, 2025. It includes detailed auditor opinions, key audit matters, and extensive financial statements such as consolidated balance sheets, income statements, cash flow statements, and equity changes. The presence of an auditor's opinion, detailed audit procedures, and comprehensive financial data confirms this is a standalone audit report rather than a full annual report or an announcement. The document length is substantial (15,000 characters) and contains actual financial data and analysis, not just a certification or announcement. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2025
2026-04-23 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.